<p>随着美国市场在科技股承压和主要指数从历史高点回落的情况下出现波动，投资者在对人工智能泡沫的担忧中密切关注机会。在如此动荡的环境中，识别潜在的被低估股票对于那些寻求利用市场低效和价格差异的投资者来说变得至关重要。</p>
<h3>基于现金流的美国十大被低估股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>当前价格</strong></td>
<td><strong>公允价值（估算）</strong></td>
<td><strong>折扣（估算）</strong></td>
</tr>
<tr>
<td>Webull (BULL)</td>
<td>$9.16</td>
<td>$17.89</td>
<td>48.8%</td>
</tr>
<tr>
<td>UMB Financial (UMBF)</td>
<td>$118.17</td>
<td>$232.81</td>
<td>49.2%</td>
</tr>
<tr>
<td>Sportradar Group (SRAD)</td>
<td>$23.11</td>
<td>$45.87</td>
<td>49.6%</td>
</tr>
<tr>
<td>Schrödinger (SDGR)</td>
<td>$18.05</td>
<td>$35.42</td>
<td>49%</td>
</tr>
<tr>
<td>Perfect (PERF)</td>
<td>$1.75</td>
<td>$3.43</td>
<td>49%</td>
</tr>
<tr>
<td>Motorcar Parts of America (MPAA)</td>
<td>$13.77</td>
<td>$26.53</td>
<td>48.1%</td>
</tr>
<tr>
<td>Mobileye Global (MBLY)</td>
<td>$11.07</td>
<td>$21.30</td>
<td>48%</td>
</tr>
<tr>
<td>Krystal Biotech (KRYS)</td>
<td>$244.65</td>
<td>$469.32</td>
<td>47.9%</td>
</tr>
<tr>
<td>FirstSun Capital Bancorp (FSUN)</td>
<td>$37.79</td>
<td>$73.32</td>
<td>48.5%</td>
</tr>
<tr>
<td>Columbia Banking System (COLB)</td>
<td>$29.24</td>
<td>$57.69</td>
<td>49.3%</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们基于现金流的 211 只被低估美国股票的完整列表。</p>
<p>在这里，我们突出了一些我们偏好的股票。</p>
<h2>Protagonist Therapeutics (PTGX)</h2>
<p><strong>概述：</strong> Protagonist Therapeutics, Inc.是一家生物制药公司，专注于开发用于血液学和血液疾病以及炎症和免疫调节疾病的肽类治疗药物，市值为 59.6 亿美元。</p>
<p><strong>运营：</strong> 该公司通过其生物技术部门产生收入，特别专注于初创企业，收入达到 2.0922 亿美元。</p>
<p><strong>公允价值折扣估算：</strong> 18.3%</p>
<p>Protagonist Therapeutics 的交易价格为 95.35 美元，低于其 116.77 美元的估算公允价值，表明基于现金流的潜在低估。该公司预计未来三年年收益增长将达到 44%，超过更广泛市场的增长预期。尽管最近出现净亏损和利润率下降，Protagonist 的有前景的产品管线包括用于真性红细胞增多症的 rusfertide，该药物已获得多个 FDA 认证并显示出积极的三期结果。</p>
<ul>
<li>我们最近的增长报告提供了 Protagonist Therapeutics 商业前景的良好预测。</li>
<li>点击这里了解 Protagonist Therapeutics 的详细财务健康报告。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/fc7d3f36-7789-4a40-8892-bf2ab67f8e26/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/fc7d3f36-7789-4a40-8892-bf2ab67f8e26/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>PTGX 截至 2025 年 12 月的折现现金流</p>
<h2>Atlantic Union Bankshares (AUB)</h2>
<p><strong>概述：</strong> Atlantic Union Bankshares Corporation 是一家银行控股公司，旗下拥有 Atlantic Union Bank，为美国消费者和企业提供一系列银行和金融服务，市值约为 52.2 亿美元。</p>
<p><strong>运营：</strong> Atlantic Union Bankshares 通过其消费者银行业务产生收入，收入为 4.1666 亿美元，以及其批发银行业务，贡献 4.7499 亿美元。</p>
<p><strong>公允价值折扣估算：</strong> 19.2%</p>
<p>Atlantic Union Bankshares 的交易价格为 36.65 美元，相较于其基于折现现金流分析的公允价值估算 45.36 美元被低估。该公司预计未来三年年收益增长将达到 41.5%，超过市场预期。然而，最近的股东稀释和低预期的股本回报率带来了挑战。尽管存在这些问题，Atlantic Union 的股息收益率在最近提高至 4.5% 后仍然具有吸引力，得益于最近几个季度强劲的净利息收入增长。</p>
<ul>
<li>我们精心准备的 Atlantic Union Bankshares 增长报告暗示其未来财务前景可能比最近的结果更强劲。</li>
<li>点击这里深入了解 Atlantic Union Bankshares 的完整分析健康报告。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/39dc53db-0edc-4efe-9bce-4b97187c1c94/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/39dc53db-0edc-4efe-9bce-4b97187c1c94/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>AUB 截至 2025 年 12 月的折现现金流</p>
<h2>Tapestry (TPR)</h2>
<p><strong>概述：</strong> Tapestry, Inc.是一家在北美、大中华区、其他亚洲地区及国际市场提供配饰和生活方式品牌产品的公司，市值约为 252.1 亿美元。</p>
<p><strong>运营：</strong> 该公司的收入来自其各个业务部门：Coach 为 58.6 亿美元，Kate Spade 为 11.7 亿美元，Stuart Weitzman 为 1.76 亿美元。</p>
<p><strong>公允价值折扣估算：</strong> 10.5%</p>
<p>Tapestry 最近的财务表现突显了其作为基于现金流的被低估股票的潜力。该公司报告第一季度净收入大幅增加至 2.748 亿美元，且每股收益显著高于去年。尽管债务水平较高和内部人士抛售，Tapestry 的股票交易价格为 123.21 美元，低于估算的公允价值 137.73 美元，得益于未来三年年利润增长预测为 24.6% 和自 2024 年 11 月以来总计 20 亿美元的持续股票回购。</p>
<ul>
<li>我们编制的增长报告表明 Tapestry 的未来前景可能向好。</li>
<li>点击探索我们在 Tapestry 资产负债表健康报告中的详细发现。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4cf6cfa0-4c9d-498d-a423-dd756aaefde7/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4cf6cfa0-4c9d-498d-a423-dd756aaefde7/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>TPR 截至 2025 年 12 月的折现现金流</p>
<h2>总结</h2>
<ul>
<li>点击这里解锁我们基于现金流的 211 只被低估美国股票的全面列表。</li>
<li>拥有这些企业的股份？将您的持股整合到 Simply Wall St 的投资组合中，以获取通知和详细的股票报告。</li>
<li>使用 Simply Wall St 应用程序提升您的投资能力，享受跨越每个大洲的市场情报免费访问。</li>
</ul>
<h2>想探索一些替代方案吗？</h2>
<ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>通过稳健的分红支付者来多样化您的投资组合，以应对潜在的市场波动。</li>
<li>通过显示强劲增长潜力的公司来充实您的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
</ul>
<p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，采用无偏见的方法，我们的文章并不构成财务建议。它不构成买入或卖出任何股票的推荐，也不考虑您的目标或财务状况。</strong> 我们旨在为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
<p>国防与灾难的移动基础设施</p>
<p>下一波机器人技术不是类人型的。它是完全自主的塔，在 30 分钟内提供 5G、ISR 和雷达，覆盖任何地方。</p>
<p>在下一轮合同之前获取投资者简报</p>
<p>代表 CiTech 赞助</p>

AUB.PRA

<p>这篇文章讨论了 2025 年 12 月三只可能被低估的股票：Protagonist Therapeutics、Atlantic Union Bankshares 和 Tapestry。Protagonist Therapeutics 的交易价格低于其公允价值，且增长预测乐观。Atlantic Union Bankshares 同样被低估，预计将实现显著的盈利增长。尽管债务水平较高，Tapestry 仍显示出强劲的利润增长。文章强调了在市场波动中识别被低估股票的重要性，并提供了一份基于现金流的 211 只被低估的美国股票的综合名单</p>

<p>As the United States market experiences fluctuations with tech shares under pressure and major indices retreating from record highs, investors are keenly observing opportunities amid concerns of an AI bubble. In such a volatile environment, identifying potentially undervalued stocks becomes crucial for those seeking to capitalize on market inefficiencies and price discrepancies.</p>
<div class="lb-trans"><p>随着美国市场在科技股承压和主要指数从历史高点回落的情况下出现波动，投资者在对人工智能泡沫的担忧中密切关注机会。在如此动荡的环境中，识别潜在的被低估股票对于那些寻求利用市场低效和价格差异的投资者来说变得至关重要。</p>
</div><h3>Top 10 Undervalued Stocks Based On Cash Flows In The United States</h3>
<div class="lb-trans"><h3>基于现金流的美国十大被低估股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Current Price</strong></td>
<td><strong>Fair Value (Est)</strong></td>
<td><strong>Discount (Est)</strong></td>
</tr>
<tr>
<td>Webull (BULL)</td>
<td>$9.16</td>
<td>$17.89</td>
<td>48.8%</td>
</tr>
<tr>
<td>UMB Financial (UMBF)</td>
<td>$118.17</td>
<td>$232.81</td>
<td>49.2%</td>
</tr>
<tr>
<td>Sportradar Group (SRAD)</td>
<td>$23.11</td>
<td>$45.87</td>
<td>49.6%</td>
</tr>
<tr>
<td>Schrödinger (SDGR)</td>
<td>$18.05</td>
<td>$35.42</td>
<td>49%</td>
</tr>
<tr>
<td>Perfect (PERF)</td>
<td>$1.75</td>
<td>$3.43</td>
<td>49%</td>
</tr>
<tr>
<td>Motorcar Parts of America (MPAA)</td>
<td>$13.77</td>
<td>$26.53</td>
<td>48.1%</td>
</tr>
<tr>
<td>Mobileye Global (MBLY)</td>
<td>$11.07</td>
<td>$21.30</td>
<td>48%</td>
</tr>
<tr>
<td>Krystal Biotech (KRYS)</td>
<td>$244.65</td>
<td>$469.32</td>
<td>47.9%</td>
</tr>
<tr>
<td>FirstSun Capital Bancorp (FSUN)</td>
<td>$37.79</td>
<td>$73.32</td>
<td>48.5%</td>
</tr>
<tr>
<td>Columbia Banking System (COLB)</td>
<td>$29.24</td>
<td>$57.69</td>
<td>49.3%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>当前价格</strong></td>
<td><strong>公允价值（估算）</strong></td>
<td><strong>折扣（估算）</strong></td>
</tr>
<tr>
<td>Webull (BULL)</td>
<td>$9.16</td>
<td>$17.89</td>
<td>48.8%</td>
</tr>
<tr>
<td>UMB Financial (UMBF)</td>
<td>$118.17</td>
<td>$232.81</td>
<td>49.2%</td>
</tr>
<tr>
<td>Sportradar Group (SRAD)</td>
<td>$23.11</td>
<td>$45.87</td>
<td>49.6%</td>
</tr>
<tr>
<td>Schrödinger (SDGR)</td>
<td>$18.05</td>
<td>$35.42</td>
<td>49%</td>
</tr>
<tr>
<td>Perfect (PERF)</td>
<td>$1.75</td>
<td>$3.43</td>
<td>49%</td>
</tr>
<tr>
<td>Motorcar Parts of America (MPAA)</td>
<td>$13.77</td>
<td>$26.53</td>
<td>48.1%</td>
</tr>
<tr>
<td>Mobileye Global (MBLY)</td>
<td>$11.07</td>
<td>$21.30</td>
<td>48%</td>
</tr>
<tr>
<td>Krystal Biotech (KRYS)</td>
<td>$244.65</td>
<td>$469.32</td>
<td>47.9%</td>
</tr>
<tr>
<td>FirstSun Capital Bancorp (FSUN)</td>
<td>$37.79</td>
<td>$73.32</td>
<td>48.5%</td>
</tr>
<tr>
<td>Columbia Banking System (COLB)</td>
<td>$29.24</td>
<td>$57.69</td>
<td>49.3%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 211 stocks from our Undervalued US Stocks Based On Cash Flows screener.</p>
<div class="lb-trans"><p>点击这里查看我们基于现金流的 211 只被低估美国股票的完整列表。</p>
</div><p>Here we highlight a subset of our preferred stocks from the screener.</p>
<div class="lb-trans"><p>在这里，我们突出了一些我们偏好的股票。</p>
</div><h2>Protagonist Therapeutics (PTGX)</h2>
<div class="lb-trans"><h2>Protagonist Therapeutics (PTGX)</h2>
</div><p><strong>Overview:</strong> Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on developing peptide therapeutics for hematology and blood disorders, as well as inflammatory and immunomodulatory diseases, with a market cap of $5.96 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Protagonist Therapeutics, Inc.是一家生物制药公司，专注于开发用于血液学和血液疾病以及炎症和免疫调节疾病的肽类治疗药物，市值为 59.6 亿美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue from its biotechnology segment, specifically focusing on startups, amounting to $209.22 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司通过其生物技术部门产生收入，特别专注于初创企业，收入达到 2.0922 亿美元。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 18.3%</p>
<div class="lb-trans"><p><strong>公允价值折扣估算：</strong> 18.3%</p>
</div><p>Protagonist Therapeutics is trading at US$95.35, below its estimated fair value of US$116.77, suggesting potential undervaluation based on cash flows. The company forecasts a significant 44% annual earnings growth over the next three years, outpacing the broader market's growth expectations. Despite recent net losses and declining profit margins, Protagonist's promising pipeline includes rusfertide for polycythemia vera, which has received multiple FDA designations and demonstrated positive Phase 3 results.</p>
<div class="lb-trans"><p>Protagonist Therapeutics 的交易价格为 95.35 美元，低于其 116.77 美元的估算公允价值，表明基于现金流的潜在低估。该公司预计未来三年年收益增长将达到 44%，超过更广泛市场的增长预期。尽管最近出现净亏损和利润率下降，Protagonist 的有前景的产品管线包括用于真性红细胞增多症的 rusfertide，该药物已获得多个 FDA 认证并显示出积极的三期结果。</p>
</div><ul>
<li>Insights from our recent growth report point to a promising forecast for Protagonist Therapeutics' business outlook.</li>
<li>Click here to discover the nuances of Protagonist Therapeutics with our detailed financial health report.</li>
</ul>
<div class="lb-trans"><ul>
<li>我们最近的增长报告提供了 Protagonist Therapeutics 商业前景的良好预测。</li>
<li>点击这里了解 Protagonist Therapeutics 的详细财务健康报告。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/fc7d3f36-7789-4a40-8892-bf2ab67f8e26/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/fc7d3f36-7789-4a40-8892-bf2ab67f8e26/chart/dcf?theme=light"/></p>
<p>PTGX Discounted Cash Flow as at Dec 2025</p>
<div class="lb-trans"><p>PTGX 截至 2025 年 12 月的折现现金流</p>
</div><h2>Atlantic Union Bankshares (AUB)</h2>
<div class="lb-trans"><h2>Atlantic Union Bankshares (AUB)</h2>
</div><p><strong>Overview:</strong> Atlantic Union Bankshares Corporation is a bank holding company for Atlantic Union Bank, offering a range of banking and financial services to consumers and businesses in the United States, with a market cap of approximately $5.22 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Atlantic Union Bankshares Corporation 是一家银行控股公司，旗下拥有 Atlantic Union Bank，为美国消费者和企业提供一系列银行和金融服务，市值约为 52.2 亿美元。</p>
</div><p><strong>Operations:</strong> Atlantic Union Bankshares generates revenue through its Consumer Banking segment, which accounts for $416.66 million, and its Wholesale Banking segment, contributing $474.99 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> Atlantic Union Bankshares 通过其消费者银行业务产生收入，收入为 4.1666 亿美元，以及其批发银行业务，贡献 4.7499 亿美元。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 19.2%</p>
<div class="lb-trans"><p><strong>公允价值折扣估算：</strong> 19.2%</p>
</div><p>Atlantic Union Bankshares, trading at $36.65, is undervalued compared to its fair value estimate of $45.36 based on discounted cash flow analysis. The company anticipates significant earnings growth of 41.5% annually over the next three years, surpassing market expectations. However, recent shareholder dilution and low forecasted return on equity pose challenges. Despite these issues, Atlantic Union's dividend yield remains attractive following a recent increase to 4.5%, supported by strong net interest income growth in recent quarters.</p>
<div class="lb-trans"><p>Atlantic Union Bankshares 的交易价格为 36.65 美元，相较于其基于折现现金流分析的公允价值估算 45.36 美元被低估。该公司预计未来三年年收益增长将达到 41.5%，超过市场预期。然而，最近的股东稀释和低预期的股本回报率带来了挑战。尽管存在这些问题，Atlantic Union 的股息收益率在最近提高至 4.5% 后仍然具有吸引力，得益于最近几个季度强劲的净利息收入增长。</p>
</div><ul>
<li>Our expertly prepared growth report on Atlantic Union Bankshares implies its future financial outlook may be stronger than recent results.</li>
<li>Delve into the full analysis health report here for a deeper understanding of Atlantic Union Bankshares.</li>
</ul>
<div class="lb-trans"><ul>
<li>我们精心准备的 Atlantic Union Bankshares 增长报告暗示其未来财务前景可能比最近的结果更强劲。</li>
<li>点击这里深入了解 Atlantic Union Bankshares 的完整分析健康报告。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/39dc53db-0edc-4efe-9bce-4b97187c1c94/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/39dc53db-0edc-4efe-9bce-4b97187c1c94/chart/dcf?theme=light"/></p>
<p>AUB Discounted Cash Flow as at Dec 2025</p>
<div class="lb-trans"><p>AUB 截至 2025 年 12 月的折现现金流</p>
</div><h2>Tapestry (TPR)</h2>
<div class="lb-trans"><h2>Tapestry (TPR)</h2>
</div><p><strong>Overview:</strong> Tapestry, Inc. is a company that offers accessories and lifestyle brand products across North America, Greater China, the rest of Asia, and internationally, with a market cap of approximately $25.21 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Tapestry, Inc.是一家在北美、大中华区、其他亚洲地区及国际市场提供配饰和生活方式品牌产品的公司，市值约为 252.1 亿美元。</p>
</div><p><strong>Operations:</strong> The company's revenue is derived from its segments: Coach at $5.86 billion, Kate Spade at $1.17 billion, and Stuart Weitzman at $176 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司的收入来自其各个业务部门：Coach 为 58.6 亿美元，Kate Spade 为 11.7 亿美元，Stuart Weitzman 为 1.76 亿美元。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 10.5%</p>
<div class="lb-trans"><p><strong>公允价值折扣估算：</strong> 10.5%</p>
</div><p>Tapestry's recent financial performance highlights its potential as an undervalued stock based on cash flows. The company reported a substantial increase in net income to US$274.8 million for the first quarter, with earnings per share rising significantly from the previous year. Despite high debt levels and insider selling, Tapestry's shares are trading at US$123.21, below the estimated fair value of US$137.73, supported by strong profit growth forecasts of 24.6% annually over the next three years and ongoing share buybacks totaling US$2 billion since November 2024.</p>
<div class="lb-trans"><p>Tapestry 最近的财务表现突显了其作为基于现金流的被低估股票的潜力。该公司报告第一季度净收入大幅增加至 2.748 亿美元，且每股收益显著高于去年。尽管债务水平较高和内部人士抛售，Tapestry 的股票交易价格为 123.21 美元，低于估算的公允价值 137.73 美元，得益于未来三年年利润增长预测为 24.6% 和自 2024 年 11 月以来总计 20 亿美元的持续股票回购。</p>
</div><ul>
<li>The growth report we've compiled suggests that Tapestry's future prospects could be on the up.</li>
<li>Click to explore a detailed breakdown of our findings in Tapestry's balance sheet health report.</li>
</ul>
<div class="lb-trans"><ul>
<li>我们编制的增长报告表明 Tapestry 的未来前景可能向好。</li>
<li>点击探索我们在 Tapestry 资产负债表健康报告中的详细发现。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4cf6cfa0-4c9d-498d-a423-dd756aaefde7/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/4cf6cfa0-4c9d-498d-a423-dd756aaefde7/chart/dcf?theme=light"/></p>
<p>TPR Discounted Cash Flow as at Dec 2025</p>
<div class="lb-trans"><p>TPR 截至 2025 年 12 月的折现现金流</p>
</div><h2>Summing It All Up</h2>
<div class="lb-trans"><h2>总结</h2>
</div><ul>
<li>Unlock our comprehensive list of 211 Undervalued US Stocks Based On Cash Flows by clicking here.</li>
<li>Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.</li>
<li>Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里解锁我们基于现金流的 211 只被低估美国股票的全面列表。</li>
<li>拥有这些企业的股份？将您的持股整合到 Simply Wall St 的投资组合中，以获取通知和详细的股票报告。</li>
<li>使用 Simply Wall St 应用程序提升您的投资能力，享受跨越每个大洲的市场情报免费访问。</li>
</ul>
</div><h2>Want To Explore Some Alternatives?</h2>
<div class="lb-trans"><h2>想探索一些替代方案吗？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>通过稳健的分红支付者来多样化您的投资组合，以应对潜在的市场波动。</li>
<li>通过显示强劲增长潜力的公司来充实您的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation.</strong> We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，采用无偏见的方法，我们的文章并不构成财务建议。它不构成买入或卖出任何股票的推荐，也不考虑您的目标或财务状况。</strong> 我们旨在为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>国防与灾难的移动基础设施</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波机器人技术不是类人型的。它是完全自主的塔，在 30 分钟内提供 5G、ISR 和雷达，覆盖任何地方。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一轮合同之前获取投资者简报</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>代表 CiTech 赞助</p>
</div>

2025 年 12 月可能被低估的三只股票